Drug intelligence / Profile preview

poly(amidoamine) dendrimer

Development stage: Phase 1
Lead developer: Egymedicalpedia
Modality: Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

Poly(amidoamine) (PAMAM) dendrimer is a repetitively branched, three-dimensional nanomolecule being investigated by Egymedicalpedia for the treatment of white spot lesions (WSLs) in dental enamel. As a biomimetic remineralizing agent, PAMAM dendrimers promote enamel remineralization by adsorbing mineral deposits and facilitating the restoration of demineralized enamel surfaces. In clinical trials, it is being evaluated both as a monotherapy and in combination with nano-hydroxyapatite to improve the microhardness of demineralized enamel in young adults aged 15-25 years.

Brand names: Starburst
Other names: PAMAM dendrimerpoly amido amine dendrimer

Beyond the preview

Go deeper on poly(amidoamine) dendrimer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on poly(amidoamine) dendrimer.

Explore the full profile